drugset / Trial / NCT03461575

Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome

NCT03461575

Phase 3 Completed 209 enrolled Huons Co., Ltd.
RandomizedFactorialDouble-blindTreatment

Summary

A multicenter, Randomized, Double blind, Restasis®-controlled Non-inferiority, Moisview® Eye Drops-controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients with Dry Eye Syndrome

Timeline

Start
2018-01-22
Primary completion
2018-07-12
Completion
2018-07-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 0.02 % Other
Subject Cyclosporine Peptide 0.05 % Other
Subject Trehalose Small molecule 3 % Other

Indications